FSSAI Orders Removal of ‘ORS’ from Food and Beverage Labels

New Delhi– The Food Safety and Standards Authority of India (FSSAI) has directed all food and beverage manufacturers to immediately remove the term “ORS” (Oral Rehydration Solution) from product labels, citing misleading claims about health benefits.

The order aims to prevent consumer confusion, as only medically certified ORS products can use the term. Non-compliance will attract fines up to ₹10 lakh. Manufacturers have 30 days to update packaging. FSSAI emphasized stricter enforcement to protect public health.

Background: Public Interest Litigation

The regulatory intervention follows a nearly decade-long campaign by Hyderabad-based paediatrician Dr. Sivaranjani Santosh against sugar-rich beverages falsely marketed as ORS. In 2022, she filed a Public Interest Litigation (PIL) in the Telangana High Court challenging beverages that claimed to be ORS but failed to meet WHO-recommended electrolyte and glucose standards.

Her petition highlighted the potential health risks, especially to children and diabetic patients, and her complaints reached the Ministry of Health and Family Welfare, prompting regulatory scrutiny.

Court and Regulatory Actions

The Telangana High Court directed FSSAI and the Drug Controller General of India to respond, recognising the public health implications of misleading ORS claims.

In April 2022, FSSAI issued its first restriction, but in July the regulator temporarily allowed companies holding valid trademarks to continue production until the Controller General of Patents, Designs and Trademarks issued a final decision.

Health Risks from Mislabelled Beverages

WHO-approved ORS has a total osmolarity of 245 mOsm/L, with precise quantities of sodium, potassium, chloride, and dextrose. In contrast, many marketed products contained up to 120 grams of sugar per litre, with minimal electrolytes, posing serious health risks.

Related Posts

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

Pak-made illegal cosmetics recovered from Itwari shop

Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Pak-made illegal cosmetics recovered from Itwari shop

Pak-made illegal cosmetics recovered from Itwari shop

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert